Cognitive performance of MDMA-Treated rhesus monkeys: Sensitivity to serotonergic challenge

Neuropsychopharmacology

Volumn 27, Issue 6, 2002, Pages 993-1005

  Taffe, Michael A ^a   Davis, Sophia A ^a   Yuan, Jie ^b   Schroeder, Richard ^a   Hatzidimitriou, George ^b   Parsons, Loren H ^a   Ricaurte, George A ^b   Gold, Lisa H ^a,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c PFIZER INC   (United States)

Author keywords

8 OH DPAT; Attention; Ketanserin; mCPP; MDMA; Memory

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; AMPHETAMINE DERIVATIVE; BROMIDE; DOPAMINE; KETANSERIN;

ABSTINENCE; ALERTNESS; ANIMAL EXPERIMENT; ARTICLE; ATTENTION; CADAVER; CEREBROSPINAL FLUID EXAMINATION; CHRONIC TOXICITY; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; HAND MOVEMENT; LONG TERM EXPOSURE; MALE; MEMORY; METABOLITE; MOTOR CONTROL; MOTOR PERFORMANCE; NEOCORTEX; NONHUMAN; PRIORITY JOURNAL; REACTION TIME; REINFORCEMENT; RHESUS MONKEY; SEROTONIN RELEASE; SPATIAL MEMORY; SUSTAINED RELEASE PREPARATION; WORKING MEMORY;

ANIMALS; BRAIN; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYINDOLEACETIC ACID; MACACA MULATTA; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; REACTION TIME; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0036898951     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00380-9     Document Type: Article

References (42)

1. Abraham M.D., Cohen P.D.A., Jan van Til R., Langemeijer M.P.S. Licit and illicit drug use in Amsterdam III. Developments in Drug Use 1987-1997:1998;CEDRO, Amsterdam.
2. Bhattachary S., Powell J.H. Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or 'ecstasy'. evidence for cognitive impairment Psychol Med. 31:2001;647-658.
3. Bolla K.I., McCann U.D., Ricaurte G.A. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology. 51:1998;1532-1537. [see comments].
4. Clark J.D., Baldwin R.L., Bayne K.A., Brown M.J., Gebhart G.F., Gonder J.C., Gwathmey J.K., Keeling M.E., Kohn D.F., Robb J.W., Smith O.A., Steggarda J.-A.D., Vandenbergh J.G., White W.J., Williams-Blangero S., VandeBerg J.L. Guide for the Care and Use of Laboratory Animals. 1996;Institute of Laboratory Animal Resources, National Research Council, Washington DC.
5. Croft R.J., Mackay A.J., Mills A.T., Gruzelier J.G. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology (Berl). 153:2001;373-379.
6. DeNoble V.J., Schrack L.M., Reigel A.L., DeNoble K.F. Visual recognition memory in squirrel monkeys. effects of serotonin antagonists on baseline and hypoxia-induced performance deficits Pharmacol Biochem Behav. 39:1991;991-996.
7. Fischer C., Hatzidimitriou G., Wlos J., Katz J., Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J Neurosci. 15:1995;5476-5485.
8. Frederick D.L., Ali S.F., Gillam M.P., Gossett J., Slikker W., Paule M.G. Acute effects of dexfenfluramine (d-FEN) and methylenedioxymethamphetamine (MDMA) before and after short-course, high-dose treatment. Ann NY Acad Sci. 844:1998;183-190.
9. Gouzoulis-Mayfrank E., Daumann J., Tuchtenhagen F., Pelz S., Becker S., Kunert H.J., Fimm B., Sass H. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry. 68:2000;719-725.
10. Hatzidimitriou G., McCann U.D., Ricaurte G.A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously. factors influencing abnormal recovery J Neurosci. 19:1999;5096-5107.
11. Hibell B., Andersson B., Ahlstrom S., Balakireva O., Bjarnason T., Kokkevi A., Morgan M. The 1999 ESPAD Report. Alcohol and other drug use among students in 30 European countries (Summary):2000;Stockholm, Sweden, The Swedish National Institute of Public Health.
12. Insel T.R., Battaglia G., Johannessen J.N., Marra S., De Souza E.B. 3,4-Methylenedioxymethamphetamine ("Ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther. 249:1989;713-720.
13. Johnston L.D., O'Malley P.M., Bachman J.G. Monitoring the Future. National Survey Results on Drug Use, 1975-2000. Volume I: Secondary School Students (NIH Publication No. 01-4924):2001;National Institute on Drug Abuse, Bethesda, MD. a.
14. Johnston L.D., O'Malley P.M., Bachman J.G. Monitoring the Future. National Survey Results on Drug Use, 1975-2000. Volume II: College Students and Adults Ages 19-40 (NIH Publication No. 01-4925):2001;National Institute on Drug Abuse, Bethesda, MD. b.
15. McCann U.D., Mertl M., Eligulashvili V., Ricaurte G.A. Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") users. a controlled study Psychopharmacology (Berl). 143:1999;417-425.
16. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet. 352:1998;1433-1437. [see comments].
17. McKearney J.W. Effects of serotonin agonists on operant behavior in the squirrel monkey. quipazine, MK-212, trifluoromethylphenylpiperazine, and chlorophenylpiperazine Pharmacol Biochem Behav. 35:1990;181-185.
18. McKenna D.J., Peroutka S.J. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J Neurochem. 54:1990;14-22.
19. Morgan M.J. Memory deficits associated with recreational use of "Ecstasy" (MDMA). Psychopharmacology (Berl). 141:1999;30-36.
20. Morgan M.J. Ecstasy (MDMA). a review of its possible persistent psychological effects Psychopharmacology (Berl). 152:2000;230-248.
21. Parrott A.C. Human research on MDMA (3,4-methylene-dioxymethamphetamine) neurotoxicity. cognitive and behavioural indices of change Neuropsychobiology. 42:2000;17-24.
22. Peroutka S.J. Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "Ecstasy") on an undergraduate campus. N Engl J Med. 317:1987;1542-1543. [letter].
23. Pope H.G. Jr., Ionescu-Pioggia M., Pope K.W. Drug use and life style among college undergraduates. a 30-year longitudinal study Am J Psychiatry. 158:2001;1519-1521.
24. Ramsey M., Spiller J. Drug Misuse Declared. Results of the 1996 British Crime Survey:1997;Home Office, RSD, London.
25. Reneman L., Booij J., Schmand B., van den Brink W., Gunning B. Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology (Berl). 148:2000;322-324.
26. Reneman L., Lavalaye J., Schmand B., de Wolff F.A., van den Brink W., den Heeten G.J., Booij J. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). preliminary findings Arch Gen Psychiatry. 58:2001;901-906.
27. Ricaurte G.A., DeLanney L.E., Wiener S.G., Irwin I., Langston J.W. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res. 474:1988;359-363. a.
28. Ricaurte G.A., Forno L.S., Wilson M.A., DeLanney L.E., Irwin I., Molliver M.E., Langston J.W. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 260:1988;51-55. b.
29. Ricaurte G.A., Martello A.L., Katz J.L., Martello M.B. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates. neurochemical observations J Pharmacol Exp Ther. 261:1992;616-622.
30. Ricaurte G.A., Yuan J., McCann U.D. (+/-)3,4-Methylenedioxymethamphetamine ("Ecstasy")-induced serotonin neurotoxicity. studies in animals Neuropsychobiology. 42:2000;5-10.
31. Rodgers J. Cognitive performance amongst recreational users of "ecstasy" Psychopharmacology (Berl). 151:2000;19-24.
32. Schuster P., Lieb R., Lamertz C., Wittchen H.U. Is the use of ecstasy and hallucinogens increasing? Results from a community study. Eur Addict Res. 4:1998;75-82.
33. Semple D.M., Ebmeier K.P., Glabus M.F., O'Carroll R.E., Johnstone E.C. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("Ecstasy") users. Br J Psychiatry. 175:1999;63-69.
34. Steele T.D., McCann U.D., Ricaurte G.A. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"). pharmacology and toxicology in animals and humans Addiction. 89:1994;539-551.
35. Taffe M.A., Weed M.R., Davis S., Huitron-Resendiz S., Schroeder R., Parsons L.H., Henriksen S.J., Gold L.H. Functional consequences of repeated (+/-)3,4-methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neuropsychopharmacology. 24:2001;230-239.
36. Taffe M.A., Weed M.R., Gold L.H. Scopolamine alters rhesus monkey performance on a novel neuropsychological testing battery. Cogn Brain Res. 8:1999;203-212.
37. Verkes R.J., Gijsman H.J., Pieters M.S., Schoemaker R.C., de Visser S., Kuijpers M., Pennings E.J., de Bruin D., Van de Wijngaart G., Van Gerven J.M., Cohen A.F. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl). 153:2001;196-202.
38. Weed M.R., Gold L.H. The effects of dopaminergic agents on reaction time in rhesus monkeys. Psychopharmacology (Berl). 137:1998;33-42.
39. Weed M.R., Taffe M.A., Polis I., Roberts A.C., Robbins T.W., Koob G.F., Bloom F.E., Gold L.H. Performance norms for a rhesus monkey neuropsychological testing battery. Acquisition and long-term performance Cogn Brain Res. 8:1999;184-201.
40. Winsauer P.J., Bixler M.A., Mele P.C. Comparison of the effects of typical and atypical anxiolytics on learning in monkeys and rats. J Pharmacol Exp Ther. 276:1996;1111-1127.
41. Winsauer P.J., McCann U.D., Yuan J., Delatte M.S., Stevenson M.W., Ricaurte G.A., Moerschbaecher J.M. Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration. Psychopharmacology (Berl). 159:2002;388-396.
42. Zakzanis K.K., Young D.A. Memory impairment in abstinent MDMA ("Ecstasy") users. a longitudinal investigation Neurology. 56:2001;966-969.